Literature DB >> 18083536

Hemoglobin and overt nephropathy complications in type 1 diabetes.

Baqiyyah Conway1, Linda Fried, Tevor Orchard.   

Abstract

PURPOSE: Anemia tends to be more severe and occur earlier in individuals with diabetic nephropathy. We thus examined whether hemoglobin (HGB) relates to end-stage renal disease (ESRD), coronary artery disease (CAD), and all cause mortality in type 1 diabetes (T1D) subjects with overt nephropathy (ON).
METHODS: We prospectively followed up 174 individuals with childhood-onset T1D and ON (albumin excretion rate >200 microg/min in multiple urine samples) from the Pittsburgh Epidemiology of Diabetes Complications Study cohort for 12 years. One hundred forty persons had ON at baseline, whereas another 34 were followed up from their incidence of ON as determined by biennial examinations.
RESULTS: Baseline HGB inversely predicted ESRD (hazard ratio [HR] = 0.70, 0.61-0.80) and mortality (HR = 0.84, 0.72-0.98), but not CAD (HR = 0.91, 0.79-1.0). After adjustment for sex, diabetes duration, and other known risk factors, HGB remained significantly predictive of ESRD (HR = 0.72, 0.61-0.85), but not CAD (HR = 0.94, 0.80-1.10) or overall mortality (HR = 0.92, 0.77-1.10). However, in those who never progressed to ESRD, HGB was significantly predictive of mortality (HR = 0.59, 0.39-0.89). After including ESRD as a time-dependent, HGB was significantly predictive of overall mortality (HR = 0.75, 0.59-0.93). Gender-specific analyses, although limited by sample size, suggests similarity in the association between absolute HGB and ESRD in both genders, but differences for CAD and mortality.
CONCLUSION: Our data suggest that in T1D with ON, a higher HGB level is associated not only with reduced risk of ESRD, but also of mortality, particularly in those who do not develop ESRD. HGB, even in the clinically normal range, is able to predict long-term complications in those with T1D and ON.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18083536      PMCID: PMC2707087          DOI: 10.1016/j.annepidem.2007.07.110

Source DB:  PubMed          Journal:  Ann Epidemiol        ISSN: 1047-2797            Impact factor:   3.797


  25 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

3.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

Authors:  Tilman B Drüeke; Francesco Locatelli; Naomi Clyne; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Hans-Ulrich Burger; Armin Scherhag
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

4.  The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience.

Authors:  Georgia Pambianco; Tina Costacou; Demetrius Ellis; Dorothy J Becker; Ronald Klein; Trevor J Orchard
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

5.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

6.  Anemia and diabetes in the absence of nephropathy.

Authors:  Kathrine J Craig; John D Williams; Stephen G Riley; Hilary Smith; David R Owens; Debbie Worthing; Ivor Cavill; Aled O Phillips
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

7.  Incidence of end-stage renal disease among persons with diabetes--United States, 1990-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-11-04       Impact factor: 17.586

8.  Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction.

Authors:  A Al-Ahmad; W M Rand; G Manjunath; M A Konstam; D N Salem; A S Levey; M J Sarnak
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

9.  Anemia with erythropoietin deficiency occurs early in diabetic nephropathy.

Authors:  D R Bosman; A S Winkler; J T Marsden; I C Macdougall; P J Watkins
Journal:  Diabetes Care       Date:  2001-03       Impact factor: 19.112

10.  Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Mark J Sarnak; Hocine Tighiouart; Guruprasad Manjunath; Bonnie MacLeod; John Griffith; Deeb Salem; Andrew S Levey
Journal:  J Am Coll Cardiol       Date:  2002-07-03       Impact factor: 24.094

View more
  6 in total

Review 1.  Haptoglobin genotype and its role in diabetic cardiovascular disease.

Authors:  Tina Costacou; Andrew P Levy
Journal:  J Cardiovasc Transl Res       Date:  2012-03-24       Impact factor: 4.132

2.  Effect of high density lipoprotein cholesterol on the relationship of serum iron and hemoglobin with kidney function in diabetes.

Authors:  Ashley N Williams; Baqiyyah N Conway
Journal:  J Diabetes Complications       Date:  2017-03-29       Impact factor: 2.852

3.  Prediction of proliferative diabetic retinopathy with hemoglobin level.

Authors:  Baqiyyah N Conway; Rachel G Miller; Ronald Klein; Trevor J Orchard
Journal:  Arch Ophthalmol       Date:  2009-11

Review 4.  Patient selection and vitamin E treatment in diabetes mellitus.

Authors:  Hagit Goldenstein; Nina S Levy; Yisrael T Lipener; Andrew P Levy
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-03

5.  Are hemoglobin levels elevated in type 1 diabetes?

Authors:  Baqiyyah N Conway; Rachel G Miller; Trevor J Orchard
Journal:  Diabetes Care       Date:  2009-11-16       Impact factor: 19.112

Review 6.  Clinical predictive factors in diabetic kidney disease progression.

Authors:  Nicholas J Radcliffe; Jas-Mine Seah; Michele Clarke; Richard J MacIsaac; George Jerums; Elif I Ekinci
Journal:  J Diabetes Investig       Date:  2016-06-08       Impact factor: 4.232

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.